D
Douglas L. Boggs
Researcher at Yale University
Publications - 34
Citations - 2184
Douglas L. Boggs is an academic researcher from Yale University. The author has contributed to research in topics: Schizophrenia & Cannabis. The author has an hindex of 17, co-authored 34 publications receiving 1939 citations. Previous affiliations of Douglas L. Boggs include University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Robert W. Buchanan,Julie Kreyenbuhl,Julie Kreyenbuhl,Deanna L. Kelly,Jason M. Noel,Douglas L. Boggs,Bernard A. Fischer,Seth Himelhoch,Beverly Fang,Eunice Peterson,Patrick R. Aquino,William R. Keller +11 more
TL;DR: An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
Journal ArticleDOI
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Robert W. Buchanan,Julie Kreyenbuhl,Julie Kreyenbuhl,Deanna L. Kelly,Jason M. Noel,Douglas L. Boggs,Bernard A. Fischer,Seth Himelhoch,Beverly Fang,Eunice Peterson,Patrick R. Aquino,William R. Keller +11 more
TL;DR: An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
Journal ArticleDOI
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.
TL;DR: Future cannabis-related policy decisions should include consideration of scientific findings, including the individual and interactive effects of CBD and THC, as well as other cannabinoid molecules currently being evaluated for medicinal purposes, separately and in combination.
Journal ArticleDOI
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Douglas L. Boggs,Toral Surti,Aarti Gupta,Swapnil Gupta,Mark J. Niciu,Brian Pittman,Ashley M. Schnakenberg Martin,Halle Thurnauer,Andrew Davies,Deepak Cyril D'Souza,Mohini Ranganathan +10 more
TL;DR: At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia, and CBD was well tolerated with no worsening of mood, suicidality, or movement side effects.
Journal ArticleDOI
Cigarette Smoking and Mortality Risk in People With Schizophrenia
Deanna L. Kelly,Robert P. McMahon,Heidi J. Wehring,Fang Liu,Kristen M. Mackowick,Douglas L. Boggs,Kimberly R. Warren,Stephanie Feldman,Joo-Cheol Shim,Raymond C. Love,Lisa B. Dixon +10 more
TL;DR: Cigarette smoking, particularly in people aged 35-54 years, contributes to an increased risk of death, and greater smoking severity significantly increases this risk.